ASH 2023 | Somatic mutations that impact alloSCT outcomes in patients with AML

Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, discusses a study investigating the impact of somatic mutations on clinical outcomes of allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML). Using next-generation sequencing (NGS), the research investigated the impact of six mutations: NPM1, FLT3-ITD, DNMT3A, RUNX1, ASXL1, and SRSF2. Results revealed improved overall survival (OS) with single mutations in NPM1 and FLT3-ITD. The best leukemia-free survival (LFS) was in patients with NPM1 mutations, regardless of other mutations, and those with ASXL1/RUNX1/SRSF2 mutations alongside wildtype NPM1 and FLT3-ITD. Conversely, the poorest LFS outcomes were observed in patients with FLT3-ITD and/or DNMT3A without NPM1 mutations or those lacking all six mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.